NO20060687L - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number
NO20060687L
NO20060687L NO20060687A NO20060687A NO20060687L NO 20060687 L NO20060687 L NO 20060687L NO 20060687 A NO20060687 A NO 20060687A NO 20060687 A NO20060687 A NO 20060687A NO 20060687 L NO20060687 L NO 20060687L
Authority
NO
Norway
Prior art keywords
compounds
new connections
pharmaceutically acceptable
formula
preparation
Prior art date
Application number
NO20060687A
Other languages
English (en)
Norwegian (no)
Inventor
Dennis Lee
Joseph P Marino
Yongdong Zhao
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20060687L publication Critical patent/NO20060687L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20060687A 2003-07-15 2006-02-13 Nye forbindelser NO20060687L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48749203P 2003-07-15 2003-07-15
PCT/US2004/022706 WO2005009993A1 (en) 2003-07-15 2004-07-15 Novel compounds

Publications (1)

Publication Number Publication Date
NO20060687L true NO20060687L (no) 2006-04-18

Family

ID=34102694

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060687A NO20060687L (no) 2003-07-15 2006-02-13 Nye forbindelser

Country Status (15)

Country Link
US (1) US20060205751A1 (is)
EP (1) EP1648885A4 (is)
JP (1) JP2007523873A (is)
KR (1) KR20060036091A (is)
CN (1) CN1852906A (is)
AU (1) AU2004259703A1 (is)
BR (1) BRPI0412694A (is)
CA (1) CA2532248A1 (is)
IL (1) IL173033A0 (is)
IS (1) IS8292A (is)
MA (1) MA27975A1 (is)
MX (1) MXPA06000538A (is)
NO (1) NO20060687L (is)
RU (1) RU2006104621A (is)
WO (1) WO2005009993A1 (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1915341A2 (en) 2005-08-15 2008-04-30 Irm, Llc Compounds and compositions as tpo mimetics
EP1957483A1 (en) 2005-12-01 2008-08-20 F.Hoffmann-La Roche Ag Novel vinylogous acids derivatives
US8053441B2 (en) 2006-02-17 2011-11-08 Janssen Pharmaceutica N.V. Pyrazolylquinazolinones as potassium channel openers
US7842713B2 (en) * 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
EP2520561B1 (en) 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
US20090142832A1 (en) * 2007-11-29 2009-06-04 James Dalton Indoles, Derivatives, and Analogs Thereof and Uses Therefor
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
EP2298767A4 (en) * 2008-07-17 2011-10-19 Asahi Kasei Pharma Corp NITROGENATED BICYCLIC AND HETEROCYCLIC COMPOUND
GEP20135793B (en) 2008-09-11 2013-03-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
DK2406253T3 (da) 2009-03-11 2013-08-12 Pfizer Benzofuranylderivater anvendt som glucokinase-inhibitorer
PL3006443T3 (pl) 2013-06-06 2018-09-28 Astellas Pharma Inc. Związek benzotiofenu
CN109701024B (zh) * 2019-03-04 2020-12-11 复旦大学 Bk通道开放剂的新用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2275461A1 (fr) * 1974-06-18 1976-01-16 Labaz Nouveaux stabilisants des polymeres et copolymeres du chlorure de vinyle
CH624395A5 (is) * 1976-01-08 1981-07-31 Ciba Geigy Ag
US4863958A (en) * 1984-06-20 1989-09-05 Merck Frosst Canada, Inc. Benzofuran derivatives useful as inhibitors of mammalian leukotriene biosynthesis
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
DE3738238A1 (de) * 1987-11-11 1989-05-24 Bayer Ag Bis-indolyl-ethylen-aldehyde
DE3738237A1 (de) * 1987-11-11 1989-05-24 Bayer Ag Bis-indolyl-ethylen
DK0528762T3 (da) * 1991-08-15 1997-08-25 Ciba Geigy Ag N-acyl-N-heterocyclyl- eller naphthylalkyl-aminosyrer som angiotensin II antagonister
US5374721A (en) * 1992-10-14 1994-12-20 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
CA2144763A1 (en) * 1992-10-14 1994-04-28 George D. Hartman Fibrinogen receptor antagonists
JPH07223371A (ja) * 1993-04-30 1995-08-22 Ricoh Co Ltd 感熱記録材料
US5639906A (en) * 1994-10-11 1997-06-17 The United States Of America As Represented By The Department Of Health And Human Services Fluorescent and NMR sensitive pH indicators
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
FR2751966B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
US6630496B1 (en) * 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
US6506758B2 (en) * 1997-12-24 2003-01-14 Smithkline Beecham Laboratoires Pharmceutiques Indole derivatives useful A.O. for the treatment of osteoporosis
GB9914371D0 (en) * 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
DE10009000A1 (de) * 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
US6858739B2 (en) * 2000-06-14 2005-02-22 Warner-Lambert Company Indole and benzimidazole 15-lipoxygenase inhibitors
US20020037912A1 (en) * 2000-08-11 2002-03-28 Leahy Ellen M. Factor viia inhibitors
WO2002051805A1 (de) * 2000-12-27 2002-07-04 Bayer Aktiengesellschaft Indol-derivate

Also Published As

Publication number Publication date
IL173033A0 (en) 2006-06-11
BRPI0412694A (pt) 2006-10-03
RU2006104621A (ru) 2006-08-27
WO2005009993A1 (en) 2005-02-03
AU2004259703A1 (en) 2005-02-03
IS8292A (is) 2006-02-09
MXPA06000538A (es) 2006-03-30
US20060205751A1 (en) 2006-09-14
MA27975A1 (fr) 2006-07-03
EP1648885A1 (en) 2006-04-26
KR20060036091A (ko) 2006-04-27
JP2007523873A (ja) 2007-08-23
CN1852906A (zh) 2006-10-25
EP1648885A4 (en) 2009-10-21
CA2532248A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
NO20061454L (no) Compounds having CRTH2 antagonist activity
NO20055219L (no) Nye forbindelser
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
NO20050828L (no) lndol-3-svovelderivater
NO20060687L (no) Nye forbindelser
NO20050065L (no) Kjemiske forbindelser
NO20056130L (no) Nye substituerte 3-svovelindoler
NO20064282L (no) Morfolinforbindelser
NO20070981L (no) Substituerte oksazolidinoner og deres anvendelse innenfor feltet blodkoagulasjon.
NO20045461L (no) Nye pyridazin 3-(2H)-on derivater som PDE4-inhibitorer
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20041041L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
NO20062726L (no) Nye pyridazin-3(2H)-on derivater
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
WO2002060458A3 (en) Compositions and method of tissue superoxygenation
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
MXPA03012013A (es) Derivados de 1-oxa-2,8-diaza-spiro[4,5]dec-2-eno sustituidos como medicamento para el tratamiento de dolor.
NO20050294L (no) Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser
NO20055977L (no) Nye benzimidazolderivater
NO20062591L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20055766L (no) Positive modulatorer av nikotinacetylcholinreseptorer
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren

Legal Events

Date Code Title Description
RE Reestablishment of rights (par. 72 patents act)
FC2A Withdrawal, rejection or dismissal of laid open patent application